Treatment of chronic myeloid leukemia in relapse after umbilical cord blood transplantation.
Umbilical cord blood (UCB) is increasingly used as a source of hematopoietic progenitor cells for allotransplantation. Donor-derived buffy coat cells are considered optimal treatment for leukemia relapses after transplantation of allogeneic bone marrow. Experience with relapses after UCB transplants are sparse. Here we report a girl who received an UCB transplant for chronic myeloid leukemia, relapsed after three years, failed to respond to donor buffy coat cells, but achieved a complete hematologic, cytogenetic, and molecular remission on interferon-alpha.
V
V
Bogdanić
I
I
Aurer
B
B
Labar
V
V
Hitrec
D
D
Nemet
M
M
Mrsić
D002675:Child, Preschool; D005260:Female; D005312:Fetal Blood; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D007951:Leukemia, Myeloid / Q000473:pathology* / Q000628:therapy*; D012008:Recurrence
D016898:Interferon-alpha